Neuroblastoma Precision Trial (NCT02868268)
N2015-01: Neuroblastoma Precision Trial
🩺 Plain-English Summary (8th-Grade Level)
This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established multi-institutional infrastructure and Translational Genomics Research Institute GEM sequencing platform for acquisition and gene panel sequencing of relapsed biological specimens in relapsed/refractory neuroblastoma (rNB) including those obtained from the bone, bone marrow or soft tissue. Our primary aim is to identify subgroups of rNB patients who have potentially targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor-associated macrophage infiltration and/or programmed death ligand \[PD-L1\] expression) biomarkers in rNB. Additional potential novel biomarkers will also be evaluated and reported in this cohort of patients.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Los Angeles — Los Angeles, California
Age range: 1 Year to 30 Years
🧪 Interventions in This Study
- Gene panel sequencing of tumor specimens (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Children's Hospital Los Angeles — Los Angeles, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Children Hospital of Colorado — Aurora, Colorado
- Children's Healthcare of Atlanta — Atlanta, Georgia
- Children's Memorial Hospital - Chicago — Chicago, Illinois
- Childrens Hospital Boston, Dana-Farber Cancer Institute. — Boston, Massachusetts
- C.S Mott Children's Hospital — Ann Arbor, Michigan
- University of North Carolina — Chapel Hill, North Carolina
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Cook Children's Healthcare System — Fort Worth, Texas
- Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuroblastoma
- Open-Label Study of 18F-mFBG for Imaging Neuroblastoma — Los Angeles, California
- Neuroblastoma Maintenance Therapy Trial — Birmingham, Alabama
- Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow — Indianapolis, Indiana
- A Study of N9 Chemotherapy in Children With Neuroblastoma — New York, New York
- A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma — San Francisco, California
Explore by condition: All Neuroblastoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.